No, Jardiance (empagliflozin) should NOT be started to treat lung fibrosis in this patient with advanced COPD.
Jardiance is not indicated for, approved for, or supported by clinical evidence for the treatment of pulmonary fibrosis in humans. The FDA-approved indications for empagliflozin are limited to type 2 diabetes mellitus, heart failure, and cardiovascular risk reduction—there is no approval or guideline support for treating lung fibrosis 1.
Why This Question Arises (and Why the Answer is No)
The Preclinical Research Context
Animal studies have shown that empagliflozin can reduce bleomycin-induced pulmonary fibrosis in mice and rats through mechanisms involving:
- Reduction of oxidative stress and inflammatory cytokines (IL-6, TNF-α, TGF-β1) 2
- Modulation of ferroptosis and autophagy pathways 3
- Improved survival rates and decreased hydroxyproline content in lung tissue 2
However, these are exclusively animal model studies with no human clinical trial data demonstrating efficacy or safety for pulmonary fibrosis treatment.
The Critical Gap: No Human Evidence
The only human study involving empagliflozin and lung disease examined patients with type 2 diabetes, cardiovascular disease, AND COPD 4. This study showed:
- Empagliflozin reduced cardiovascular outcomes and mortality in diabetic patients with COPD
- It did NOT evaluate or demonstrate any effect on lung fibrosis, pulmonary function, or COPD progression
- The benefits were cardiovascular, not pulmonary
What IS Supported for Pulmonary Fibrosis
For patients with progressive pulmonary fibrosis, the evidence-based treatments are:
- Pirfenidone and nintedanib are the only FDA-approved antifibrotic agents 5, 6, 7
- These agents slow (but do not reverse) fibrotic progression
- They are indicated for idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung diseases
The Correct Management Approach for This Patient
For the Advanced COPD Component
Following GOLD guidelines 8, 9:
- Inhaled bronchodilators (LAMA, LABA, or combination) as primary therapy
- Smoking cessation if still smoking—the single most important intervention
- Pulmonary rehabilitation to improve symptoms and quality of life
- Influenza and pneumococcal vaccinations
- Consider long-term oxygen therapy if severe resting hypoxemia (PaO₂ ≤55 mmHg or SaO₂ ≤88%)
- For advanced disease refractory to medical therapy: evaluate for lung volume reduction surgery, bullectomy, or lung transplantation 8
For the Basal Lung Scarring/Fibrotic Changes
- Determine if this represents progressive pulmonary fibrosis requiring antifibrotic therapy
- If progressive fibrosis is documented (decline in FVC ≥10% or ≥5% with worsening symptoms/imaging over 12 months), consider referral to pulmonary fibrosis specialist for evaluation of pirfenidone or nintedanib 5, 6
- This patient may have combined pulmonary fibrosis and emphysema (CPFE), which carries worse prognosis with high risk of pulmonary hypertension and lung cancer 10
If the Patient Has Comorbid Diabetes or Heart Failure
Only then would empagliflozin be appropriate—but for those cardiovascular/metabolic indications, not for lung fibrosis 4:
- Type 2 diabetes with cardiovascular disease
- Heart failure with reduced or preserved ejection fraction
- The cardiovascular benefits would apply even in the presence of COPD, but would not treat the lung disease itself
Critical Pitfalls to Avoid
- Do not extrapolate animal model data to human treatment decisions—the mechanistic studies are hypothesis-generating only
- Do not use SGLT2 inhibitors off-label for pulmonary fibrosis—there is no safety or efficacy data in humans
- Do not delay evidence-based antifibrotic therapy (pirfenidone/nintedanib) if progressive fibrosis is documented
- Do not overlook standard COPD management while focusing on the fibrotic component
- Recognize CPFE as a distinct entity requiring specialized management and close monitoring for complications 10